alendronate has been researched along with calcitriol in 61 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.64) | 18.7374 |
| 1990's | 7 (11.48) | 18.2507 |
| 2000's | 36 (59.02) | 29.6817 |
| 2010's | 15 (24.59) | 24.3611 |
| 2020's | 2 (3.28) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bettschen-Camin, L; Felix, R; Fleisch, H; Stronski, SA; Trechsel, U; Wetterwald, A | 1 |
| Ammann, P; Bonjour, JP; Budayr, AA; Burckhardt, P; Gertz, B; Jaquet-Müller, F; Jenzer, A; Rizzoli, R; Thiébaud, D; Zysset, E | 1 |
| Chambers, TJ; Fuller, K; Owens, JM | 1 |
| Bowman, AR; Epstein, S; Jee, WS; Ma, Y; Sass, DA; Yuan, Z | 1 |
| Apone, S; Eyre, DR; Lee, MY | 1 |
| Meunier, PJ | 1 |
| Gnudi, S; Malavolta, N; Ripamonti, C; Veronesi, M; Zanardi, M | 1 |
| Eisman, JA; Sambrook, PN | 1 |
| Kashyap, AS; Kashyap, S | 1 |
| Galbavý, S; Paukovic, J; Wendlová, J | 1 |
| Compston, JE | 1 |
| Blackwell, PJ; Cawte, SA; Fowler, I; Hosking, DJ; Lawson, N; Masud, T; Sahota, O; San, P | 1 |
| Gutteridge, DH; Kent, GN; Lim, EM; Stuckey, BG; Ward, LC | 1 |
| Bonfante, L; Carraro, G; Crepaldi, G; D'Angelo, A; Dalle Carbonare, L; Giannini, S; Marchini, F; Nobile, M; Rigotti, P; Sartori, L; Zaninotto, M | 1 |
| Akoglu, E; Arikan, H; Koc, M; Ozener, C; Tuglular, S | 1 |
| Body, JJ; Correa-Rotter, R; Cumming, DC; Dore, RK; Gaich, GA; Hodsman, AB; Kulkarni, PM; Miller, PD; Papaioannou, A; Peretz, A; Scheele, WH | 1 |
| Carreño, L; Esbrit, P; García-Flores, M; Gómez-García, L; Martinez, ME; Sabando, P | 1 |
| Eisman, JA; Henderson-Briffa, KN; Kotowicz, M; Naganathan, V; Nash, P; Nicholson, GC; Sambrook, PN; Styles, CB | 1 |
| Haviko, T; Maasalu, K; Märtson, A | 1 |
| Jeffery, JR; Karpinski, ME; Leslie, WD; Nickerson, PW; Rush, DN | 1 |
| Addesso, V; Lo, SH; Mancini, D; Maybaum, S; McMahon, DJ; Namerow, PB; Pardi, S; Shane, E; Staron, RB; Zucker, M | 1 |
| Lindsay, R | 1 |
| SoRelle, R | 1 |
| Gutteridge, DH | 1 |
| Drexel, H; Hoefle, G; Holzmueller, H | 1 |
| Dejardin, A; Devogelaer, JP; Goffin, E | 1 |
| Doggrell, SA | 1 |
| Akiyama, Y; Hara, K; Kobayashi, M | 1 |
| Altundal, H; Gursoy, B | 1 |
| Addesso, V; Cohen, A; Mancini, D; Maybaum, S; McMahon, DJ; Namerow, P; Shane, E; Staron, RB | 1 |
| Boyd, IW; Calcino, LJ; McEwen, J | 1 |
| Akyildiz, M; Atamaz, F; Hepguler, S; Karasu, Z; Kilic, M | 1 |
| Ahn, C; Baek, K; Byun, D; Chung, Y; Kang, M; Kim, D; Kim, H; Kim, Y; Lim, SK; Min, Y; Mok, J; Myoung, S; Rhee, Y | 1 |
| Altundal, H; Göker, K; Sayrak, H; Yurtsever, E | 1 |
| Bilezikian, J; Black, DM; Ensrud, K; Greenspan, S; Palermo, L; Rosen, CJ; Sellmeyer, DE | 1 |
| Barone, A; Bianchi, G; Girasole, G; Giusti, A; Palummeri, E; Pioli, G; Pizzonia, M; Razzano, M | 1 |
| Duque, G; Rivas, D | 1 |
| Ringe, JD; Schacht, E | 2 |
| Abu-Ali, S; Fotovati, A; Hayashi, K; Naito, M; Nakamura, Y | 1 |
| Chow, SK; Fauzi, AR; Goh, EM; Halim, AG; Kong, NC; Rahimah, I; Soehardy, Z; Yeap, SS | 1 |
| Lan, G; Peng, F; Peng, L; Wang, Y; Xie, X; Yu, S | 1 |
| Cosman, F; Glass, EV; Krege, JH; Mauck, KF; Recknor, C; Wermers, RA; Xie, L | 1 |
| Ahmad, AM; Durham, BH; Fraser, WD; Joshi, AA; Vora, JP; White, HD | 1 |
| Chan, SP; Othman, AZ; Yeap, SS; Zain, AA | 1 |
| Paz-Pacheco, E; Sandoval, MA | 1 |
| Lim, SK; Park, BW; Park, HS; Park, S; Rhee, Y; Song, K | 1 |
| Dalton, N; Fogelman, I; Fraser, WD; Hampson, G; Inaoui, R; Turner, C | 1 |
| Cho, S; Choi, YS; Lee, BS; Park, HS; Park, JH; Park, KH; Seo, SK | 1 |
| Choi, YJ; Chung, YS; Kim, SH | 1 |
| Gallagher, JC; Tella, SH | 1 |
| Byun, DW; Jung, CH; Kim, CH; Kim, SJ; Kim, YJ; Mok, JO; Park, HK; Ryu, CB; Suh, KI; Yoo, MH | 1 |
| Asplin, JR; Bushinsky, DA; Culbertson, CD; Frick, KK; Granja, I; Krieger, NS | 1 |
| Assimos, DG | 1 |
| Edwards, S; Elford, C; Evans, BA; Fogelman, I; Frost, ML; Hampson, G; Ishtiaq, S; Sankaralingam, A | 1 |
| Chen, DC; Cheng, Q; De Peng, Y; Hao, YQ; He, L; Hu, ZH; Liao, EY; Lin, H; Santora, AC; Song, CL; Tang, H; Wang, J; Wang, L; Wei, F; Xia, WB; You, L; Zhang, L; Zhang, ZL | 1 |
| Chen, DC; Cheng, Q; Hao, YQ; He, L; Hu, ZH; Liao, EY; Lin, H; Peng, YD; Song, CL; Tang, H; Wang, J; Wang, L; Wei, F; Xia, WB; You, L; Zhang, L; Zhang, ZL | 1 |
| Aoyama, T; Atsumi, Y; Rino, Y; Yamada, T; Yukawa, N | 1 |
| Chen, Y; Li, Y; Ma, R; Song, J; Wang, J; Wang, K; Wang, W; Wu, M; Yang, P | 1 |
6 review(s) available for alendronate and calcitriol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials.
Topics: Alendronate; Calcitonin; Calcitriol; Calcium; Calcium Fluoride; Evidence-Based Medicine; Fractures, Bone; Hormone Replacement Therapy; Humans; Osteoporosis; Parathyroid Hormone; Randomized Controlled Trials as Topic; Receptors, Estrogen; Vitamin D | 1999 |
Osteoporosis prevention and treatment.
Topics: Alendronate; Anabolic Agents; Bone Density; Calcitriol; Calcium; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Male; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk Factors; Treatment Outcome; Vitamin D | 2000 |
Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Calcitriol; Diphosphonates; Drug Therapy, Combination; Humans; Hydroxycholecalciferols; Osteoporosis; Treatment Outcome; Vitamin D | 2007 |
Controversies in osteoporosis management: antiresorptive therapy for preventing bone loss: when to use one or two antiresorptive agents?
Topics: Alendronate; Bone Density Conservation Agents; Calcitriol; Calcium, Dietary; Diphosphonates; Drug Therapy, Combination; Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride | 2013 |
Metabolic bone disorders after gastrectomy: inevitable or preventable?
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; Female; Gastrectomy; Humans; Male; Osteomalacia; Osteoporosis; Postoperative Complications; Stomach Neoplasms | 2022 |
26 trial(s) available for alendronate and calcitriol
| Article | Year |
|---|---|
Calcitriol and alendronate combination treatment in menopausal women with low bone mass.
Topics: Aged; Alendronate; Calcitriol; Calcium; Calcium Channel Agonists; Calcium, Dietary; Drug Therapy, Combination; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Phosphorus | 1999 |
A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodeling; Calcitriol; Calcium Channel Agonists; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Radiography; Spinal Diseases | 2000 |
Alendronate prevents further bone loss in renal transplant recipients.
Topics: Adult; Alendronate; Bone and Bones; Bone Density; Bone Remodeling; Calcitriol; Calcium, Dietary; Female; Humans; Kidney Transplantation; Male; Middle Aged; Osteoporosis; Parathyroid Hormone | 2001 |
Alendronate increases bone mineral density in long-term renal transplant recipients.
Topics: Absorptiometry, Photon; Adult; Alendronate; Bone Density; Calcitriol; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Postoperative Complications; Reoperation; Time Factors; Treatment Failure | 2002 |
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Body Height; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Calcitriol; Collagen; Collagen Type I; Double-Blind Method; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Teriparatide | 2002 |
Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcitriol; Calcium; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Middle Aged; Osteoporosis; Vitamin D | 2003 |
Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate.
Topics: Adult; Alendronate; Azathioprine; Bone Density; Bone Resorption; Calcitriol; Calcium Channel Agonists; Cross-Sectional Studies; Cyclosporine; Female; Humans; Immunosuppression Therapy; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Postoperative Complications; Prednisone | 2003 |
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Density; Bone Resorption; Calcitriol; Calcium; Collagen; Collagen Type I; Female; Fractures, Bone; Heart Transplantation; Humans; Immunosuppression Therapy; Male; Middle Aged; Parathyroid Hormone; Peptides; Postoperative Complications | 2004 |
Recent important clinical trials of drugs in osteoporosis.
Topics: Aged; Alendronate; Animals; Calcitriol; Drug Therapy, Combination; Exercise Therapy; Female; Heart Transplantation; Humans; Meta-Analysis as Topic; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Risk Assessment; Thiophenes | 2004 |
Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover.
Topics: Adult; Alendronate; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Calcitriol; Collagen; Collagen Type I; Female; Fractures, Bone; Heart Transplantation; Humans; Incidence; Male; Middle Aged; Peptides; Radiography; Spinal Injuries | 2006 |
Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation.
Topics: Absorptiometry, Photon; Adult; Alendronate; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcitriol; Calcium; Female; Femur; Humans; Liver Transplantation; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Parathyroid Hormone; Prospective Studies | 2006 |
Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcitriol; Collagen Type I; Double-Blind Method; Drug Combinations; Female; Femur; Humans; Hydroxycholecalciferols; Korea; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Treatment Outcome | 2006 |
Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Female; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Vitamin D | 2007 |
Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitriol; Calcium; Female; Humans; Hyperparathyroidism, Secondary; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Vitamin D Deficiency | 2007 |
A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitriol; Calcium; Calcium Carbonate; Female; Humans; Lupus Erythematosus, Systemic; Osteoporosis; Premenopause; Young Adult | 2008 |
Alendronate is effective to treat bone loss in renal transplantation recipients.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitriol; Calcium; Creatinine; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Young Adult | 2008 |
Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Drug Administration Schedule; Female; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Patient Selection; Raloxifene Hydrochloride; Teriparatide; Treatment Outcome; United States; Vitamin D | 2009 |
Effect of oral phosphate and alendronate on bone mineral density when given as adjunctive therapy to growth hormone replacement in adult growth hormone deficiency.
Topics: Administration, Oral; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcitriol; Circadian Rhythm; Collagen Type I; Cyclic AMP; Drug Therapy, Combination; Female; Human Growth Hormone; Humans; Male; Middle Aged; Parathyroid Hormone; Peptides; Phosphates; Recombinant Proteins | 2011 |
Vitamin D levels: its relationship to bone mineral density response and disease activity in premenopausal Malaysian systemic lupus erythematosus patients on corticosteroids.
Topics: Absorptiometry, Photon; Adrenal Cortex Hormones; Adult; Alendronate; Asian People; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcitriol; Calcium; Dietary Supplements; Female; Humans; Lupus Erythematosus, Systemic; Malaysia; Osteoporosis; Premenopause; Time Factors; Treatment Outcome; Vitamin D; Young Adult | 2012 |
Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study.
Topics: Alendronate; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Calcitriol; Calcium, Dietary; Cholecalciferol; Collagen Type I; Combined Modality Therapy; Dietary Supplements; Double-Blind Method; Drug Combinations; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Dropouts; Peptides; Postmenopause; Republic of Korea | 2013 |
Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women.
Topics: Alendronate; Calcitriol; Dosage Forms; Drug Combinations; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Republic of Korea; Tablets; Tablets, Enteric-Coated | 2013 |
Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females.
Topics: Administration, Oral; Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Calcitriol; Drug Combinations; Endoscopy, Digestive System; Esophagus; Female; Gastric Mucosa; Humans; Middle Aged; Postmenopause; Predictive Value of Tests; Republic of Korea; Sex Factors; Tablets, Enteric-Coated; Time Factors; Treatment Outcome; Vitamins | 2013 |
The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells.
Topics: Alendronate; Angiopoietin-1; Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; Cell Line; Cell Line, Tumor; Culture Media, Conditioned; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression; Humans; Imidazoles; Mice; Middle Aged; Osteoblasts; Osteoporosis, Postmenopausal; Peptide Fragments; Procollagen; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2015 |
Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.
Topics: Aged; Alendronate; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Calcitriol; Cholecalciferol; Drug Combinations; Female; Femur Neck; Hip Joint; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Tablets; Vitamin D | 2015 |
Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitriol; China; Cholecalciferol; Dietary Supplements; Female; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Time Factors; Treatment Outcome | 2018 |
The use of bone turnover markers for monitoring the treatment of osteoporosis in postmenopausal females undergoing total knee arthroplasty: a prospective randomized study.
Topics: Administration, Oral; Aged; Alendronate; Arthroplasty, Replacement, Knee; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcitriol; Calcium; Collagen Type I; Female; Humans; Middle Aged; Monitoring, Physiologic; Osteoporosis, Postmenopausal; Peptide Fragments; Peptides; Procollagen; Prospective Studies; Vitamin D | 2021 |
29 other study(ies) available for alendronate and calcitriol
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Bisphosphonates inhibit 1,25-dihydroxyvitamin D3-induced increase of osteocalcin in plasma of rats in vivo and in culture medium of rat calvaria in vitro.
Topics: Alendronate; Animals; Calcitriol; Calcium-Binding Proteins; Clodronic Acid; Culture Techniques; Diphosphonates; DNA; Male; Osteoblasts; Osteocalcin; Proline; Rats; Rats, Inbred Strains; Skull | 1988 |
Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
Topics: Alendronate; Calcitriol; Calcium; Creatinine; Diphosphonates; Female; Humans; Hypercalcemia; Male; Neoplasms; Pamidronate; Parathyroid Hormone; Parathyroid Hormone-Related Protein; Phosphorus; Proteins | 1994 |
Osteoclast activation: potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism.
Topics: Acid Phosphatase; Alendronate; Animals; Animals, Newborn; Calcitriol; Cells, Cultured; Mice; Osteoclasts; Rats; Rats, Wistar; Receptors, Calcitonin | 1997 |
Alendronate prevents cyclosporin A-induced osteopenia in the rat.
Topics: Administration, Oral; Alendronate; Analysis of Variance; Animals; Body Weight; Bone Diseases, Metabolic; Bone Resorption; Calcitriol; Calcium; Cyclosporine; Disease Models, Animal; Image Processing, Computer-Assisted; Immunosuppressive Agents; Injections, Subcutaneous; Male; Osteocalcin; Osteoclasts; Parathyroid Hormone; Random Allocation; Rats; Rats, Sprague-Dawley; Tibia | 1997 |
Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone.
Topics: Acid Phosphatase; Alendronate; Amino Acids; Animals; Anti-Inflammatory Agents; Biomarkers; Bone Marrow; Bone Resorption; Calcitonin; Calcitriol; Cells, Cultured; Chromatography, High Pressure Liquid; Collagen; Collagen Type I; Culture Media; Dentin; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Femur; Humans; Hydrocortisone; Isoenzymes; Mice; Mice, Inbred BALB C; Osteoclasts; Peptide Biosynthesis; Peptides; Receptors, Calcitonin; Tartrate-Resistant Acid Phosphatase | 1997 |
Hypoparathyroidism unmasked by alendronate.
Topics: Aged; Alendronate; Calcitriol; Calcium Carbonate; Calcium Channel Agonists; Female; Humans; Hypocalcemia; Hypoparathyroidism; Osteoporosis, Postmenopausal | 2000 |
[Paget's disease of bone--treatment with alendronate, calcium and calcitriol].
Topics: Aged; Alendronate; Calcitriol; Calcium; Drug Therapy, Combination; Humans; Male; Osteitis Deformans | 1999 |
Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?
Topics: Aged; Alendronate; Calcitriol; Calcium Channel Agonists; Calcium Channel Blockers; Estrogen Antagonists; Etidronic Acid; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures | 2000 |
Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
Topics: Alendronate; Calcitriol; Calcium; Cervical Vertebrae; Diphosphonates; Female; Humans; Hypocalcemia; Hypoparathyroidism; Middle Aged; Osteitis Deformans; Pamidronate; Pelvis; Scapula; Tibia; Time Factors; Treatment Outcome | 2001 |
Alendronate interacts with the inhibitory effect of 1,25(OH)2D3 on parathyroid hormone-related protein expression in human osteoblastic cells.
Topics: Alendronate; Bone Resorption; Calcitriol; Calcium Signaling; Cells, Cultured; Dose-Response Relationship, Drug; Drug Interactions; Gene Expression; Humans; Kinetics; Osteoblasts; Osteocalcin; Parathyroid Hormone-Related Protein; Peptide Hormones; Receptors, Calcitriol; RNA, Messenger | 2003 |
Treatment of children with Osteogenesis imperfecta in Estonia.
Topics: Administration, Oral; Adolescent; Alendronate; Bone Density; Calcitriol; Calcium Channel Agonists; Child; Child, Preschool; Drug Therapy, Combination; Estonia; Female; Follow-Up Studies; Fractures, Bone; Humans; Infant; Male; Osteogenesis Imperfecta; Outcome Assessment, Health Care; Retrospective Studies; Time Factors | 2003 |
Bone loss after cardiac transplantation.
Topics: Alendronate; Biomarkers; Bone Density; Bone Resorption; Calcitriol; Collagen; Collagen Type I; Fractures, Bone; Heart Transplantation; Humans; Parathyroid Hormone; Peptides; Postoperative Complications | 2004 |
Two markers complement each other in identifying risk.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Alendronate; Biomarkers; C-Reactive Protein; Calcitriol; Cholesterol, LDL; Coronary Disease; Female; Heart Transplantation; Humans; Kidney Diseases; Male; Osteoporosis; Phospholipases A; Postoperative Complications; Randomized Controlled Trials as Topic; Risk | 2004 |
Alendronate versus calcitriol for prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Resorption; Calcitriol; Drug Therapy, Combination; Estrogens; Humans; Organ Transplantation; Osteoporosis, Postmenopausal | 2004 |
Alendronate versus calcitriol for prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Resorption; Calcitriol; Calcium; Cyclosporine; Drug Therapy, Combination; Heart Transplantation; Humans; Immunosuppressive Agents; Kidney Diseases; Vitamin D | 2004 |
Alendronate versus calcitriol for prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Density; Bone Resorption; Calcitriol; Creatinine; Cyclosporine; Female; Heart Transplantation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Male; Prednisone; Renal Insufficiency; Tacrolimus | 2004 |
Effects of vitamin K2 (menatetrenone) and alendronate on bone mineral density and bone strength in rats fed a low-magnesium diet.
Topics: Alendronate; Alkaline Phosphatase; Animals; Body Weight; Bone and Bones; Bone Density; Calcitriol; Calcium; Elasticity; Femur; Hydroxyproline; Magnesium; Magnesium Deficiency; Male; Osteocalcin; Parathyroid Hormone; Rats; Rats, Wistar; Stress, Mechanical; Urine; Vitamin K 2 | 2004 |
The influence of alendronate on bone formation after autogenous free bone grafting in rats.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone Regeneration; Bone Transplantation; Calcitriol; Calcium; Cell Count; Femur; Injections, Subcutaneous; Male; Osteoblasts; Osteocalcin; Parathyroid Hormone; Phosphates; Rats; Rats, Wistar; Statistics, Nonparametric | 2005 |
A study of codispensing with sodium alendronate in Australia.
Topics: Alendronate; Australia; Bone Density Conservation Agents; Calcitriol; Cohort Studies; Databases, Factual; Female; Gastrointestinal Agents; Gastrointestinal Diseases; Histamine H2 Antagonists; Humans; Male; Middle Aged; Osteoporosis; Sex Distribution | 2006 |
Inhibitory effect of alendronate on bone resorption of autogenous free bone grafts in rats.
Topics: Alendronate; Amino Acids; Animals; Bone Density Conservation Agents; Bone Resorption; Bone Transplantation; Calcitriol; Calcium; Creatinine; Male; Osteoclasts; Parathyroid Hormone; Rats; Rats, Wistar; Statistics, Nonparametric | 2007 |
Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells.
Topics: Adipocytes; Alendronate; Anabolic Agents; Bone and Bones; Calcitriol; Cell Differentiation; Cell Proliferation; Cells, Cultured; Humans; Mesenchymal Stem Cells; Osteoclasts; PPAR gamma | 2007 |
Effect of preoperative combined treatment with alendronate and calcitriol on fixation of hydroxyapatite-coated implants in ovariectomized rats.
Topics: Absorptiometry, Photon; Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Calcitriol; Coated Materials, Biocompatible; Disease Models, Animal; Drug Combinations; Durapatite; Female; Femur; Osteoporosis; Ovariectomy; Preoperative Care; Prostheses and Implants; Rats; Rats, Wistar | 2008 |
Potential of alfacalcidol for reducing increased risk of falls and fractures.
Topics: Accidental Falls; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitriol; Calcium; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Fractures, Bone; Glucocorticoids; Humans; Hydroxycholecalciferols; Lumbar Vertebrae; Male; Meta-Analysis as Topic; Osteoporosis; Risk Factors; Time Factors; Treatment Outcome; Vitamin D | 2009 |
Primary hyperparathyroidism with classic and severe skeletal involvement.
Topics: Adenoma; Alendronate; Calcitriol; Calcium Carbonate; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Hyperparathyroidism, Primary; Middle Aged; Osteoporosis; Parathyroid Hormone; Parathyroid Neoplasms; Parathyroidectomy; Postoperative Care; Radiography; Recurrence; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2010 |
Effect of a 300 000-IU loading dose of ergocalciferol (Vitamin D2) on circulating 1,25(OH)2-vitamin D and fibroblast growth factor-23 (FGF-23) in vitamin D insufficiency.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Ergocalciferols; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Male; Middle Aged; Osteoporosis; Postmenopause; Vitamin D; Vitamin D Deficiency | 2013 |
Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcitriol; Drug Therapy, Combination; Female; Hand Strength; Humans; Interleukin-6; Lumbar Vertebrae; Middle Aged; Muscle Strength; Osteoporosis, Postmenopausal; Parathyroid Hormone; Postmenopause; Sarcopenia | 2013 |
Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcitriol; Calcium, Dietary; Disease Models, Animal; Genotype; Hypercalciuria; Intestinal Absorption; Intestinal Mucosa; Kidney; Kidney Calculi; Male; Phenotype; Rats; Rats, Sprague-Dawley; Time Factors | 2014 |
Re: Persistence of 1,25D-induced hypercalciuria in alendronate treated genetic hypercalciuric stone-forming rats fed a low calcium diet.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Calcitriol; Calcium, Dietary; Hypercalciuria; Kidney; Kidney Calculi; Male | 2014 |